Radiolabeled Diagnostic Peptides
2 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- PendetidePendetide, also known as capromab pendetide or ProstaScint, is an FDA‑approved radiopharmaceutical used for diagnostic imaging of prostate cancer. The agent consists of a murine monoclonal antibody (7E11‑C5.3) linked to the chelator GYK‑DTPA and labeled with indium‑111. After intravenous injection, it enables single‑photon emission computed tomography (SPECT) to visualize prostate‑specific membrane antigen (PSMA)–expressing tissue, primarily to assess the extent of primary or metastatic disease.
- Vipivotide tetraxetanVipivotide tetraxetan (Lu-177 PSMA-617, marketed as Pluvicto) is a radiolabelled small‑molecule that binds prostate‑specific membrane antigen (PSMA) and delivers beta‑particle radiation to PSMA‑expressing cancer cells. It is prescribed for patients with metastatic castration‑resistant prostate cancer (mCRPC) whose disease has progressed after prior systemic therapies.